DNLI
NASDAQ
US
Denali Therapeutics Inc. - Common Stock
$20.65
▲ +$0.97
(+4.93%)
Vol 1.6M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.6B
ROE
-40.8%
Margin
-36.5%
D/E
0.60
Beta
0.98
52W
$11–$24
Wall Street Consensus
25 analysts · Apr 202611
Strong Buy
12
Buy
2
Hold
0
Sell
0
Strong Sell
92.0%
Buy Rating
Price Chart
Similar Stocks
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
LEGN
Legend Biotech Corp
$4.0B
DYN
Dyne Therapeutics Inc
$3.2B
TNGX
Tango Therapeutics Inc
$1.2B
TWST
Twist Bioscience Corp
$1.9B
CPRX
Catalyst Pharmaceuticals Inc
P/E 13.2
$2.9B
ARQT
Arcutis Biotherapeutics Inc
$3.6B
VERA
Vera Therapeutics, Inc
$3.5B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.76 | $-0.73 | +$0.03 |
| Sep 2025 | $-0.77 | $-0.74 | +$0.03 |
| Jun 2025 | $-0.73 | $-0.72 | +$0.01 |
| Mar 2025 | $-0.70 | $-0.78 | $-0.08 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$114.8M | -$133.0M | -$124.1M | -$126.9M | -$128.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -40.8% | -31.4% | -31.4% | -31.4% | -40.8% | -40.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -36.5% | -36.5% | -36.5% | -36.5% | -36.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.54 | 0.54 | 0.54 | 0.54 | 0.60 | 0.60 |
| Current Ratio | 10.27 | 10.27 | 10.27 | 10.27 | 9.79 | 9.79 |
Key Ratios
ROA (TTM)
-36.4%
P/S (TTM)
7.57
P/B
2.4
EPS (TTM)
$-2.81
CF/Share
$-0.77
52W High
$24.35
52W Low
$10.57
$10.57
52-Week Range
$24.35
Financial Health
Free Cash Flow
-$100.1M
Net Debt
-$168.6M
Cash
$205.3M
Total Debt
$36.8M
As of Dec 31, 2025
How does DNLI compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DNLI valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.6
▼
41%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
2.4
▼
3%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DNLI profitability vs Biotechnology peers
ROE
-40.8%
▲
39%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-36.5%
▲
87%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-36.4%
▲
22%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
DNLI financial health vs Biotechnology peers
D/E ratio
0.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
9.8
▲
121%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.0
▲
1%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
DNLI fundamentals radar
DNLI
Peer median
Industry
DNLI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DNLI vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
WATTS RYAN J
Chief Executive Officer · Jan 06
35198 shs
SCHUTH ALEXANDER O
Chief Financial Officer · Jan 06
17218 shs
Last 90 days
Top Holders
Top 5: 33.0%Vanguard Group Inc
8.23%
$237.1M
Blackrock Inc.
8.02%
$230.9M
BAILLIE GIFFORD & CO
7.76%
$223.6M
T. Rowe Price Investment Ma…
4.57%
$131.7M
Temasek Holdings (Private) …
4.42%
$127.4M
As of Dec 31, 2025
Latest News
No related news yet